Doctors in Germany say a single infusion of a gene-editing treatment fixed the faulty gene behind an inherited liver and lung disease in about half of the gene copies they checked in one patient’s liver1. The patient, a 66-year-old man, has alpha-1 antitrypsin deficiency, often shortened to AATD or “alpha-1”1. The results come from the first small study of the treatment in people and were reported in the Journal of Hepatology1.
What happened
The treatment is called YOLT-202. It uses a technique called base editing, which changes a single letter of DNA rather than cutting the DNA strand1. The editing tools are packed into lipid nanoparticles, tiny fat bubbles that carry them to the liver after an infusion into a vein1.
The man received one infusion at the lowest dose the researchers had planned to test1. About two and a half months later, a genetic analysis of his liver tissue showed that the disease-causing letter had been corrected in 54% to 57% of gene copies1. The researchers also reported “stable and clinically meaningful” levels of working alpha-1 antitrypsin protein in his blood after treatment1. A liver biopsy (a small tissue sample) found no detectable stray edits near the target and no edits at other places in the DNA1.
“This is a transformative moment,” said researcher Michael Ott of Hannover Medical School1. Lead researcher Simon Krooss, also of Hannover Medical School, said the correction rate at such a low dose was “truly surprising”1.
The disease being targeted
Alpha-1 antitrypsin is a protein made in the liver. In the blood it holds back an enzyme that white blood cells release to fight infection. Without enough of the protein, that enzyme can attack healthy lung tissue2. AATD comes from changes in a gene called SERPINA11.
Most severe cases are in people who carry two copies of one particular faulty version, called Z (doctors write this as Pi*ZZ)1. In these people the faulty Z protein folds wrongly and builds up inside the liver, while too little of it reaches the bloodstream. Over time this can lead to liver disease and emphysema, a lung disease that makes breathing hard1. The condition affects roughly 1 in 1,500 to 3,500 people of European ancestry, and about 100,000 people in the United States are estimated to carry two Z copies2.
Current care does not fix the cause. The main treatment, called augmentation therapy, gives people alpha-1 antitrypsin protein taken from donated blood for the rest of their lives. It can raise protein levels in the lungs and slow lung damage, but it does not prevent liver damage2.
The evidence so far
The study is described as a Phase I/Ia trial, an early test whose main job is to check safety in a small number of people1. The report covers one patient1.
The result is best understood as a mix. After treatment, the man’s liver became a patchwork: some cells had both gene copies corrected, some had one corrected, and some were unchanged1. Overall, the researchers say his liver moved from a two-faulty-copy pattern toward a pattern like that of a carrier with one working copy1. The editing was done without a virus as the carrier, which the researchers point to as evidence that the fat-bubble delivery worked efficiently in liver tissue1.
What it does not show yet
- Whether it helps health. The measures were gene copies and blood protein levels. The report does not show whether the treatment prevents emphysema or liver damage1.
- How long it lasts. The DNA result reported is from about 2.5 months after the infusion1. Ott said the team is “a step closer to offering permanent” therapies, which is a hope rather than a measured result1.
- Whether it works the same in others. One person cannot show how often the treatment works, how much it varies between people, or what side effects might appear in a larger group.
- Exact protein numbers. The coverage we read describes the blood protein levels as stable and meaningful but does not give the figures1.
Who is behind it
The researchers quoted are from Hannover Medical School in Germany, including Michael Ott, Simon Krooss and Heiner Wedemeyer1. The report we read does not say who funded the study or which company develops YOLT-202, so Biohack cannot describe funding or possible conflicts of interest here1.
The researchers see wider uses. Wedemeyer said the findings “open the door to treating a wide range of hereditary liver disorders, including coagulation diseases” and could support future treatments for very rare variants found in single patients1. The coverage also says the technique might one day be used against some infectious diseases1. None of these uses has been tested in this study.
How it fits the field
This is not the only attempt to fix AATD with base editing. Beam Therapeutics, a US company, is testing a similar one-time treatment called BEAM-302. It also uses fat bubbles to deliver a base editor to the liver and is designed to make the same kind of single-letter correction to the Z version of the gene3.
In March 2025, Beam reported early results from its first three dose groups, describing what CRISPR Medicine News called the first clinical genetic correction of a disease-causing mutation with base editing2. At the highest of those doses, the company said average total alpha-1 antitrypsin in the blood reached 12.4 micromolar at day 28, above the 11 micromolar level considered protective, and the faulty Z protein fell by up to 78%2. The company said side effects were mild to moderate, mostly small rises in liver enzymes and short infusion reactions, with no serious side effects as of its data cutoff2. Those were company-reported results.
The US Food and Drug Administration has given BEAM-302 orphan drug status, for rare diseases, and a designation meant to speed up regenerative medicine treatments3. Beam’s trial plans to enroll an estimated 192 people with lung disease, liver disease or both, and its main results are expected to be complete in May 2028, according to the trial registry4. Its main goals include side-effect rates over three years and blood levels of the protein4.
Supporters of gene correction note one possible advantage over protein from donated blood: because the fix happens in the patient’s own gene, protein levels might rise naturally during infection or inflammation, as they do in healthy people2. That has not been shown in the Hannover patient.
What to watch next
- Longer follow-up of this patient, showing whether gene correction and protein levels hold over a year or more.
- Results in more patients and at higher doses in the YOLT-202 study, which so far reports only the lowest planned dose1.
- Further data from Beam’s larger trial, including people with liver disease34.
- Any sign, in time, of whether these treatments change lung or liver health rather than only lab measures.
